Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease

Key Points

• The research aims to evaluate the therapeutic effects of Orai-1 inhibition in a Huntington disease model.
• Utilized a 3-nitropropionic acid (3-NPA) model in mice to induce Huntington disease symptoms.
• Administered the Orai-1 inhibitor Synta-66 to test its effects on neuroprotection.
• Conducted behavioral and biochemical assessments to evaluate treatment outcomes.
• Synta-66 treatment resulted in significant neuroprotective effects in the mice model.
• Behavioral tests showed improved motor function in treated mice compared to non-treated groups.
• Biochemical analyses indicated reduced neuronal death markers with Synta-66 administration.